Kissei’s Tavneos sales fell by almost a quarter in the three months to June. The company then cut its full-year sales forecast for the drug by around 60 per cent and more than halved its group operating-profit forecast. A product expected to help drive growth has become a serious challenge to that growth plan.
If you are considering Kissei as a customer or licensing partner, this situation may change the expected conversation. Which projects will still deserve investment? What evidence will their management team need before making a commitment? And where can you, as an external partner, make a useful contribution? The Kissei partnership opportunities have changed.
My reading is that Kissei’s need for growth remains, but any investment proposal will need to be particularly convincing. That means that there maybe a reason to reassess your approach regarding the commercial opportunity and risks as a whole.
The Financial Impact Is Substantial
The contrast between the original May forecast and Kissei’s July quarterly materials is stark: expected Tavneos sales for the year ending March 2027 fell from ¥12.7 billion to ¥5.1 billion. First-quarter sales had already declined by 23.1 per cent compared with the same quarter a year earlier.
In its 31 July earnings revision, Kissei also reduced its group sales forecast by about 7 per cent and its operating-profit forecast by about 55 per cent.
These figures describe different things: the quarterly decline is an actual result; the much larger full-year reduction is a change in expectations. This matters far beyond a one product failure. Kissei is reconsidering how a weak contribution from the expected blockbusting drug Tavneos affects the resources available for development, launches and future partnerships.
Safety and Evidence Integrity Require Different Responses
The difficulties extend well beyond disappointing sales.
On 21 May, Kissei issued a Blue Letter under instructions from Japan’s health ministry, warning about serious liver injury, including fatal cases, and strengthening monitoring requirements. It had already asked clinicians to refrain from starting new patients on Tavneos for the time being.
Separately, the FDA’s Center for Drug Evaluation and Research proposed withdrawing approval on 27 April. It cited a lack of demonstrated efficacy for the approved use and materially untrue statements in the approval application. This withdrawal proposal is a regulatory process.
In Europe, the process has already progressed further. Following the CHMP’s June recommendation, the European Commission revoked Tavneos’ marketing authorisation on 4 August. The New England Journal of Medicine also retracted the principal ADVOCATE trial publication on 29 June.
Patient safety and the reliability of efficacy evidence are distinct questions. Better safety monitoring cannot establish that a drug works. Equally, confidence in efficacy would not remove the need to investigate serious liver injury.
A Licensing Agreement Does Not Transfer All the Risk
Kissei’s August announcement explains the licensing chain: ChemoCentryx developed Tavneos, Vifor Fresenius Medical Care Renal Pharma obtained rights in specified territories, and Kissei sublicensed the Japanese rights. Amgen subsequently acquired ChemoCentryx. This structure illustrates a difficult issue for regional licensees. Responsibility towards local patients, clinicians and regulators can sit with one company while important evidence and development decisions originate elsewhere.
If you are offering an asset to a Japanese partner, expect questions that go beyond your published results. Who controls the underlying data? What can the licensee inspect independently? How are regulatory concerns communicated? Who must investigate, respond and pay when a problem emerges?
Data-access rights, audit findings, safety responsibilities and contractual obligations belong in the investment discussion from the beginning. They will materially affect what Kissei is willing to pay as the Kissei partnership opportunities are now changing.
Kissei Still Has a Growth Agenda
Kissei’s Beyond 80 strategy positions fiscal 2025–2029 as a period of growth investment. Its targets include annual sales of at least ¥110 billion and a stronger development pipeline, supported by internal discovery, in-licensing and overseas business.
The Tavneos setback makes that ambition harder to deliver. It does not, by itself, establish that Kissei has abandoned it.
There is still a portfolio to develop. The company’s pipeline published in July 2026 includes olutasidenib for relapsed or refractory acute myeloid leukaemia, linzagolix for endometriosis, cretostimogene grenadenorepvec for high-risk non-muscle-invasive bladder cancer, rovatirelin for spinocerebellar degeneration and matsupexole for Parkinson’s disease. Earlier programmes address Graves’ disease, bladder disorders and narcolepsy.
Our reading is that these programmes offer a more useful starting point than a general pitch about helping Kissei recover. You need to identify a specific development decision, evidence gap or execution problem that your company is highly qualified to address.
The same discipline applies to licensing. Therapeutic fit matters, alongside the development burden, available rights and commercial rationale. We explored that approach in our article on updating your Japan partner map after Shionogi’s IntraBio deal. A change in strategy or portfolio should prompt you to revisit your assumptions about any potential partner.
Where Your Company May Be Useful
The following are commercial hypotheses to qualify with Kissei, rather than evidence of open procurement mandates.
Independent Evidence and Safety Expertise
A specialist with relevant experience may be able to help assess data reliability, investigate safety signals or strengthen the evidence supporting a regulatory decision. The value lies in answering a defined question. What can the available data establish? Which uncertainties remain? What additional work would change the decision?
An offer built around a clear deliverable, appropriate independence and transparent methods will be more credible than a broad promise.
Focused Support for Pipeline Programmes
If you help advance specialist medicines, you probably have the necessary expertise in patient recruitment, disease-relevant models, biomarkers, clinical endpoints, diagnostics and/or trial operations. Connect your capabilities to a named programme and explain the decisions you can support. For example, a feasibility assessment should establish whether suitable Japanese sites and patients can realistically support the proposed study.
Our review of changes to clinical trials in Japan provides useful context for overseas developers. It is a starting point for planning as each asset’s requirements still need their own assessment.
External Assets with a Credible Japan Case
Kissei’s stated interest in external innovation gives suitable asset owners a reason to investigate fit. Your proposal will need to explain the unmet need, differentiation, available territorial rights and remaining development work. You should also address manufacturing readiness, evidence quality and a realistic route to commercial value in Japan.
A stronger proposition is a programme that fits Kissei’s new partnership opportunities, capabilities and justifies the investment. Assuming a product setback creates an urgent appetite for a replacement is not enough for approaching Kissei at this point.
Better Licensing and Investment Decisions
The broader lesson concerns how companies assess risk before signing a deal. Scientific, clinical, manufacturing, regulatory and contractual reviews need to inform the same investment decision. A serious issue in one area can undermine an otherwise attractive opportunity.
If you are an adviser or specialist provider, a useful first assignment might be a defined review of an evidence package, a Japan development assessment or an evaluation of a specific licensing risk. The scope should be small enough to commission and substantial enough to influence the next decision.
Make Your Proposal Easy to Evaluate
I would begin with a short proposition that answers four questions:
- Which Kissei programme or strategic priority does this support?
- What decision or practical outcome will the work enable?
- What evidence demonstrates that your team can deliver?
- What will it require from Kissei in money, time and internal resources?
Be precise about accountability, deliverables and the next decision point. Give your counterpart something they can easily explain internally. Relationships matter! A scientifically strong proposal still needs an internal sponsor who feels confident recommending both your work and your company. I discuss this in Why Japanese Targets Like You, Listen to You—and Still You Don’t Succeed.
For Kissei, the immediate responsibilities are serious. Any approach should respect the work of protecting patients and resolving questions about evidence. Commercial sensitivity means arriving with a relevant, well-supported proposition and listening carefully to whether it addresses a current priority.
Build Your Japan Strategy Around your Partner’s Decisions and Needs
If you are a supplier or asset owner, Kissei deserves a fresh assessment. The company’s growth ambitions, existing programmes and current pressures need to be considered together. Your task is to establish where your capabilities fit, who would evaluate them and what would make a first project worth approving.
Biosector can help you turn that analysis into practical business development in Japan: assessing potential partners, shaping a credible proposition, reaching the relevant teams and supporting the relationship as discussions progress.
If you are considering Kissei, or reassessing your wider Japan strategy, we would be happy to explore where your company could contribute and what a sensible first step would look like. Understanding your Japanese value proposition is key.
Book an exploratory meeting with Biosector.
Contact us at info@biosector.jp.
Source note: Public sources reviewed on 19 October 2026. Financial comparisons refer to Kissei’s May and July 2026 disclosures; the pipeline examples refer to its July publication. Potential commercial needs and suggested approaches are Biosector’s analysis, rather than statements of Kissei’s purchasing intentions.

Comments are closed